ZA944338B - Neuropeptide Y Antagonists and Agonists - Google Patents

Neuropeptide Y Antagonists and Agonists

Info

Publication number
ZA944338B
ZA944338B ZA944338A ZA944338A ZA944338B ZA 944338 B ZA944338 B ZA 944338B ZA 944338 A ZA944338 A ZA 944338A ZA 944338 A ZA944338 A ZA 944338A ZA 944338 B ZA944338 B ZA 944338B
Authority
ZA
South Africa
Prior art keywords
neuropeptide
agonists
antagonists
Prior art date
Application number
ZA944338A
Inventor
Ambikaipakan Balasubramaniam
Original Assignee
Univ Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cincinnati filed Critical Univ Cincinnati
Publication of ZA944338B publication Critical patent/ZA944338B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA944338A 1993-06-18 1994-06-17 Neuropeptide Y Antagonists and Agonists ZA944338B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7931993A 1993-06-18 1993-06-18

Publications (1)

Publication Number Publication Date
ZA944338B true ZA944338B (en) 1995-02-14

Family

ID=22149788

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA944338A ZA944338B (en) 1993-06-18 1994-06-17 Neuropeptide Y Antagonists and Agonists

Country Status (6)

Country Link
EP (1) EP0707490A1 (en)
JP (1) JPH11501281A (en)
AU (1) AU7174494A (en)
CA (1) CA2165200A1 (en)
WO (1) WO1995000161A1 (en)
ZA (1) ZA944338B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516653A (en) * 1993-12-28 1996-05-14 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US5545549A (en) 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
US5943242A (en) 1995-11-17 1999-08-24 Pact Gmbh Dynamically reconfigurable data processing system
FR2754709B1 (en) * 1996-10-23 1999-03-05 Sanofi Sa COSMETIC COMPOSITION CONTAINING AN ANTAGONIST OF GAMMA NEUROPEPTIDE RECEPTORS AND ALPHA 2 ANTAGONISTS THAT MAY BE INCORPORATED IN SUCH A COMPOSITION
US6180653B1 (en) * 1996-12-16 2001-01-30 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
US6542998B1 (en) 1997-02-08 2003-04-01 Pact Gmbh Method of self-synchronization of configurable elements of a programmable module
CN101239090A (en) 1997-04-15 2008-08-13 Csir公司 Pharmaceutical compositions having appetite suppressant activity
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
GB0217015D0 (en) * 2002-07-23 2002-08-28 Bioacta Ltd Peptide 4
JP4806628B2 (en) 2003-05-05 2011-11-02 プロビオドルグ エージー Glutaminyl cyclase inhibitor
JP2007509898A (en) 2003-11-03 2007-04-19 プロビオドルグ エージー Useful combinations for the treatment of neurological disorders
EP1713780B1 (en) 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
WO2007097742A1 (en) * 2006-02-21 2007-08-30 University Of Cincinnati Methods relating to glucocorticoid induced receptors
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN101668525A (en) 2007-03-01 2010-03-10 前体生物药物股份公司 New use of glutaminyl cyclase inhibitors
DK2142514T3 (en) 2007-04-18 2015-03-23 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
MX2011008774A (en) * 2009-02-20 2011-10-24 Ipsen Pharma Sas Cytotoxic conjugates having neuropeptide y receptor binding compound.
EP2398485A4 (en) * 2009-02-20 2013-01-09 Ipsen Pharma Sas Analogues of neuropeptide y having at least one synthetic amino acid substitution
EA021852B1 (en) * 2009-02-20 2015-09-30 Ипсен Фарма С.А.С. Analogues of neuropeptide y having proline substitution at position 34
JP5934645B2 (en) 2009-09-11 2016-06-15 プロビオドルグ エージー Heterocyclic derivatives as glutaminyl cyclase inhibitors
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
CN102791704B (en) 2010-03-10 2015-11-25 前体生物药物股份公司 The heterocycle inhibitor of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
JP6050264B2 (en) 2011-03-16 2016-12-21 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US10865185B2 (en) 2015-08-21 2020-12-15 Srx Cardio, Llc Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity
EP3337788A4 (en) 2015-08-21 2019-03-27 Portola Pharmaceuticals, Inc. Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use
US10821106B2 (en) 2015-08-21 2020-11-03 Srx Cardio, Llc Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
DK3461819T3 (en) 2017-09-29 2020-08-10 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839343A (en) * 1987-03-13 1989-06-13 Debiopharm, S.A. Preparation containing hexatriacontapeptides and methods of use
US5026685A (en) * 1988-07-15 1991-06-25 The Salk Institute For Biological Studies NPY peptide analogs
ZA896376B (en) * 1988-08-26 1990-05-30 Merrell Dow Pharma Neuropeptide y agonists

Also Published As

Publication number Publication date
WO1995000161A1 (en) 1995-01-05
CA2165200A1 (en) 1995-01-05
EP0707490A1 (en) 1996-04-24
AU7174494A (en) 1995-01-17
JPH11501281A (en) 1999-02-02

Similar Documents

Publication Publication Date Title
ZA944338B (en) Neuropeptide Y Antagonists and Agonists
EP0723556A4 (en) Fas antagonists and uses thereof
HU9202842D0 (en) Climotripsine-type proteases and inhibitors
PL336213A1 (en) Gnrh antagonists modified at positions 5 and 6
HU9301603D0 (en) Angiotensine 11 antagonists
ZA946571B (en) Sulfonate endothelin antagonists
EP0791009A4 (en) Modified neuropeptide y receptors
GB9309121D0 (en) Substituted acylating agents
IL109782A0 (en) Imidazole-5-position substituted angiotensin II antagonists and pharmaceutical compositions containing them
AP9200441A0 (en) Benzopyrans and related ltb4 antagonists
SG50426A1 (en) Lhrh antagonists
GB2281830B (en) I/q-modulator and i/q-demodulator
GB9300938D0 (en) Substituted triazolinones triazo inethiones and triazolinimines as neurotensin 11 antagonists
PL307138A1 (en) Amyline antagonists and agonists
IL104472A0 (en) Substituted hexahydro-azepinones and tetrahydro-benzazepinones
AU6361494A (en) Anhydroretinol and derivatives thereof as antagonists
GB9216776D0 (en) Composition and use
GB9501907D0 (en) Allatostatins and their use
GB9306456D0 (en) Composition and use
IE892746L (en) Neuropeptide y antagonists
GB9408859D0 (en) Composition and use
AU620432C (en) Neuropeptide Y antagonists
PL296873A1 (en) Substituted and heterocyclic phtalides
GB9303913D0 (en) Compound and use
ZA946265B (en) Nonpeptide endothelin antagonists I